Gallium Ga 68-DOTATATE

RADIATION8 trials

Conditions

Anatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate CarcinomaDigestive System Neuroendocrine TumorGanglioneuroblastomaGanglioneuromaGrade 1 MeningiomaGrade 2 MeningiomaGrade 3 Meningioma

Early Phase 1

An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors

Active, not recruitingNCT04040088

Mayo ClinicGanglioneuroblastoma, Ganglioneuroma, Neuroblastoma

Start: 2019-09-23End: 2026-07-31Target: 20Updated: 2026-03-31

Phase 1

Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas

CompletedNCT03953131

M.D. Anderson Cancer CenterMeningioma

Start: 2019-01-10End: 2023-08-30Updated: 2023-09-01

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

RecruitingNCT07150806

Joshua PalmerRecurrent Meningioma

Start: 2025-11-12End: 2026-12-31Target: 30Updated: 2025-12-22

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

RecruitingNCT07150546

Emory UniversityDigestive System Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1 +1

Start: 2025-10-14End: 2027-09-30Target: 15Updated: 2026-03-02

Phase 2

Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer

CompletedNCT03448458

Emory UniversityCastration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7

Start: 2018-02-22End: 2023-02-06Updated: 2025-07-17

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

RecruitingNCT04082520

Mayo ClinicGrade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma +2

Start: 2020-04-14End: 2031-01-06Target: 41Updated: 2025-12-11

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

Not yet recruitingNCT04529044

OHSU Knight Cancer InstituteAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma

Start: 2025-12-01End: 2026-12-20Target: 10Updated: 2025-10-30

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

RecruitingNCT05691465

National Cancer Institute (NCI)Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma +1

Start: 2023-12-27End: 2026-11-02Target: 30Updated: 2026-04-03

Related Papers

Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials

Breast Cancer Research and Treatment2023-12-209 citations

The role of 68Ga-DOTATATE for evaluation of patients with metastatic castration-resistant prostate cancer (mCRPC).